3.56

1.93% -0.07

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$3.63

Offen:

$3.59

24-Stunden-Volumen:

8.31M

Relative Volume:

0.92

Marktkapitalisierung:

$1.19B

Einnahmen:

$32.77M

Nettoeinkommen (Verlust:

$-440.22M

KGV:

-2.1317

EPS:

-1.67

Netto-Cashflow:

$-400.48M

1W Leistung:

+0.56%

1M Leistung:

-32.32%

6M Leistung:

-62.96%

1J Leistung:

-75.98%

1-Tages-Spanne:

$3.51

$3.64

1-Wochen-Bereich:

$3.33

$3.69

52-Wochen-Spanne:

$3.33

$14.77

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (671)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	3.56	1.19B	32.77M	-440.22M	-400.48M	-1.67
VRTX Vertex Pharmaceuticals Inc	492.69	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	637.36	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	589.15	35.93B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	268.46	34.75B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	267.39	28.24B	3.81B	-644.79M	-669.77M	-6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

Mar 27, 2025

Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - StockTitan

Mar 27, 2025

Mar 25, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey

Mar 25, 2025

Mar 22, 2025

1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - MSN

Mar 22, 2025

3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not - The Motley Fool

Mar 22, 2025

Mar 21, 2025

Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com

Mar 21, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Mar 21, 2025

Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan

Mar 21, 2025

Mar 18, 2025

Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha

Mar 18, 2025

Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly

Mar 18, 2025

Mar 17, 2025

Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey

Mar 17, 2025

Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 12, 2025

Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - Yahoo

Mar 12, 2025

Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR

Mar 12, 2025

Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 12, 2025

Mar 10, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat

Mar 06, 2025

Mar 05, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance

Mar 04, 2025

Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance

Mar 04, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World

Mar 04, 2025

Mar 03, 2025

Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating - Marketscreener.com

Mar 03, 2025

Rhumbline Advisers Has $2.86 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Mar 03, 2025

Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Research Analysts Set Expectations for IOVA Q1 Earnings - Defense World

Mar 03, 2025

Mar 02, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St

Mar 02, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 12-Month Low After Analyst Downgrade - Defense World

Mar 02, 2025

Mar 01, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 01, 2025

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance UK

Mar 01, 2025

Robert W. Baird Cuts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00 - MarketBeat

Mar 01, 2025

Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA) - Defense World

Mar 01, 2025

Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN

Mar 01, 2025

Feb 28, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Releases Earnings Results, Hits Expectations - MarketBeat

Feb 28, 2025

Iovance Biotherapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks

Feb 28, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat

Feb 28, 2025

New York State Common Retirement Fund Sells 98,840 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Feb 28, 2025

Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics - Benzinga

Feb 28, 2025

Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade) - Seeking Alpha

Feb 28, 2025

Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating - Marketscreener.com

Feb 28, 2025

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty - Yahoo Finance

Feb 28, 2025

IOVA stock touches 52-week low at $3.92 amid market challenges By Investing.com - Investing.com South Africa

Feb 28, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises -February 28, 2025 at 03:51 am EST - Marketscreener.com

Feb 28, 2025